Compare NX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NX | XERS |
|---|---|---|
| Founded | 1927 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 939.3M | 1.0B |
| IPO Year | 2008 | 2021 |
| Metric | NX | XERS |
|---|---|---|
| Price | $20.35 | $6.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $28.00 | $10.83 |
| AVG Volume (30 Days) | 325.3K | ★ 1.4M |
| Earning Date | 06-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,837,641,000.00 | $49,590,000.00 |
| Revenue This Year | $4.26 | $34.37 |
| Revenue Next Year | $1.77 | $22.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 43.81 | ★ 142.67 |
| 52 Week Low | $11.04 | $4.26 |
| 52 Week High | $22.90 | $10.08 |
| Indicator | NX | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 58.46 | 52.26 |
| Support Level | $18.08 | $5.76 |
| Resistance Level | $22.64 | $6.41 |
| Average True Range (ATR) | 0.81 | 0.22 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 62.94 | 50.39 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.